We update our model after the FY25 results. We now factor in a slightly higher debt ratio at similar FY26 EPRA EPS estimates based on the € 300,0m newly guided investments (acquisitions + developments) which are skewed to 2H26. This benefits mostly our FY27-28 rental income. The Armonea (Colisée) negotiations (7,0% combined total rents) are terminated with limited negative rent reversion impact included in the FY26 guidance. This results in a lower risk premium and a higher target price from € 7...
PRESS RELEASE: NACON acknowledges the press release issued today by its majority shareholder, Bigben Interactive, and announces that it is carefully assessing the consequences for its own activities. Press Release Lesquin, 17 February 2026, 20.30 pm Nacon (the ‘Company’) acknowledges the press release issued today by its majority shareholder, Bigben Interactive, and announces that it is carefully assessing the consequences for its own activities. The Company acknowledges the press release issued today by its majority shareholder, ...
COMMUNIQUE DE PRESSE: Nacon prend acte du communiqué de presse publié ce jour par son actionnaire majoritaire, la société Bigben Interactive, et annonce en évaluer attentivement les conséquences sur ses propres activités. Communiqué de presse Lesquin, 17 février 2026, à 20h30 Nacon (la « Société ») prend acte du communiqué de presse publié ce jour par son actionnaire majoritaire, la société Bigben Interactive, et annonce en évaluer attentivement les conséquences sur ses propres activités. La Société prend acte du communiqué de pr...
Aedifica: Conference call highlights. Basic-Fit: Belgian VAT increase for culture, sports and takeaway meals postponed. BE Semiconductor Industries: 4Q25 Preview, incremental strength. Kendrion: Preview - Clean into 2026. Magnum Ice Cream Company: Acquisition of Kwality Wall's launched. Retail Estates: Re-letting progress highlights portfolio quality. Semi Equipment: AMAT readthrough strength. Universal Music Group: EU Commission approves UMG's Downtown acquisition, requires full Curve Ro...
We update the performance of our ING Benelux Favourites list as well as all valuation and ranking tables for our coverage universe. Performance on the front page is dated from the 28 January 2026, while historical performance is included on the second page. The methodology for our favourites selection is based on a bottom-up approach with a focus on absolute performance with clear near-term triggers. It is a rolling list, ie, stocks can enter/exit whenever we think opportune. The ING Benelux Fav...
Aedifica: Results slightly better, guidance for the combined entity to come in Sept. CM.com: 4Q25 results – no turning point yet. D'Ieteren: Allstate reports bumper 4Q25, touts premium cuts, consensus prudent. Heijmans: Construction cool cat. Proximus: CPaaS peer Twilio 4Q25 results better than expected. Talabat: 4Q25 results, doubling down on investments. Theon International: Preview – a busy year it was.
Aedifica NV/SA: 2025 annual results Please find below a press release from Aedifica (a public regulated real estate company under Belgian law, listed on Euronext Brussels and Euronext Amsterdam), regarding its 2025 annual results. Aedifica’s Exchange Offer on all Cofinimmo shares is now open Cofinimmo shareholders are offered 1.185 new Aedifica shares for each share they tenderThe Initial Acceptance Period will close on 2 March 2026 (16:00 CET)Results of the Initial Acceptance Period are expected to be announced on 6 March, with settlement scheduled on 13 March Robust operational perform...
GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales Ipsen reported US$88M of Iqirvo® net sales in PBC for 4Q25, bringing 2025 sales to US$208M, triggering the first commercial milestone payment to GENFIT ahead of schedule1Ipsen confirmed its commitment to launch a Phase 3 in PSC, creating a new avenue for potential future upside for GENFITGENFIT’s CCA Phase 1b study progressing as planned: New dose-escalation cohort fully enrolled with no dose-limiting toxicities reported at the 21-day timepoint Phase 1b data readout ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.